Helping You Build Wealth With Honest Research
Since 1996. Read On...

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Revealed
India's Third Giant Leap

This Could be One of the Biggest Opportunities for Investors




Important: We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
By submitting your email address, you also sign up for Profit Hunter, a daily newsletter from Equitymaster
covering exciting investing ideas and opportunities in India.

AD

Indian Markets Trade in the Green
Fri, 23 Oct 01:30 pm

After opening firm, the Indian Markets continued to trade positively. Sectoral indices are trading on a positive note with stocks from the banking, pharma and oil and gas sectors leading the gains. However, capital goods stocks are witnessing selling pressure.

The BSE-Sensex is trading up 210 points (up 0.8%) and the NSE-Nifty is trading up 53 points (up 0.6%). The S&P BSE Midcap index and the S&P BSE Smallcap index are also trading in the green, both up by 0.4%. The rupee is trading at 64.87 to the US$.

Automobile stocks are trading mixed with Maharashtra Scooters and Force Motors leading the gains. As per a leading financial daily, the country's largest two-wheeler maker Hero MotoCorp is all set to enter three new countries - Argentina, Mexico and Nigeria by the end of this financial year. This is in line with the company's strategy that will help in widening its footprint across global markets.

In addition, the company is looking to sell 2.5 lakh units in the international markets this fiscal, up 25% from 2 lakh units in the previous fiscal. Besides with that, the company is also aiming to ramp up the production capacity at its Colombian facility to 4,000 units a month, from the current capacity of around 2,500-3,000 units a month.

Along with these plans, the company has recently begun its operations at a new facility at Villa Rica in Colombia, which was built with an investment of US$ 70 million.

Presently, the company sells its products in 24 countries including Sri Lanka, Nepal, Bangladesh, Egypt and Turkey in Asia, Peru, Ecuador and Colombia in South America, among others. By 2020, the company aims to be in over 50 countries with 20 plus assembly facilities globally. The stock of the company is trading down by about 0.3%.

Stocks in the pharmaceuticals space are trading on a positive note with Cadila Healthcare and Strides Acrolab witnessing maximum buying interest. According to an article in Economic Times, Sun Pharma has settled a patent litigation with US-based Acorda Therapeutics Inc over Ampyra extended-release tablets, which is used to treat multiple sclerosis patients.

As per the settlement, it that the Indian drug major can launch its generic version of the medicine in the US by 2027. The company along with its subsidiary reported the settlement agreement. Acorda Therapeutics filed the litigation in response to Sun Pharma's submission of an Abbreviated New Drug Application (ANDA) to the US Food and Drug Administration, seeking marketing approval for a generic version of Ampyra. The scrip of Sun Pharma is trading up by 0.5% on the BSE.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Indian Markets Trade in the Green". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited).

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.